An ICT decision support system for clinical interpretation of genomic data used...
An ICT decision support system for clinical interpretation of genomic data used by geneticists to rapidly and accurately pinpoint unique disease causing variants
With the increasing volume of genetic sequences, bioinformatics methods, data about variants and mutations, and research publications, clinical interpretation remains a complex and labour-intensive task. As a result, clinical inte...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Información proyecto Emedgene
Duración del proyecto: 2 meses
Fecha Inicio: 2018-01-31
Fecha Fin: 2018-04-30
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
With the increasing volume of genetic sequences, bioinformatics methods, data about variants and mutations, and research publications, clinical interpretation remains a complex and labour-intensive task. As a result, clinical interpretation became the costly piece of genetic testing, limiting scale, keeping turnaround time high, and driving up costs of a test. Moreover, after the geneticist’s work is done, clinicians still remain with partial, insufficient information to base their clinical decisions on.
Emedgene have developed an ICT platform for clinical interpretation of genomic data. The platform continuously scans all public resources and databases available, retrieves information from written publications using Natural Language Processing, and intelligently integrates the data into unified ontologies. It is the first artificial intelligence platform, modelled on the behaviour of sophisticated genomic interpreters, to automatically pinpoint the unique disease-causing variants and deliver results with solid evidence and reasoning, providing a clear path to clinical decisions.
Within the overall project, Emedgene plan to optimise the platforms interpretations capabilities, demonstrate and validate it in clinical environments, and fully establish the European commercialisation strategy.